Medicus Pharma (MDCX) Competitors $2.00 +0.02 (+1.01%) As of 11:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. CGTX, ZNTL, HLVX, COYA, OKYO, CRDL, ANEB, TCRX, ATOS, and MGNXShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Cognition Therapeutics (CGTX), Zentalis Pharmaceuticals (ZNTL), HilleVax (HLVX), Coya Therapeutics (COYA), OKYO Pharma (OKYO), Cardiol Therapeutics (CRDL), Anebulo Pharmaceuticals (ANEB), TScan Therapeutics (TCRX), Atossa Genetics (ATOS), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Cognition Therapeutics Zentalis Pharmaceuticals HilleVax Coya Therapeutics OKYO Pharma Cardiol Therapeutics Anebulo Pharmaceuticals TScan Therapeutics Atossa Genetics MacroGenics Medicus Pharma (NASDAQ:MDCX) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Which has higher earnings & valuation, MDCX or CGTX? Cognition Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.34-1.49Cognition TherapeuticsN/AN/A-$33.97M-$0.67-2.57 Does the media refer more to MDCX or CGTX? In the previous week, Cognition Therapeutics had 7 more articles in the media than Medicus Pharma. MarketBeat recorded 10 mentions for Cognition Therapeutics and 3 mentions for Medicus Pharma. Cognition Therapeutics' average media sentiment score of 0.75 beat Medicus Pharma's score of -0.17 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Medicus Pharma Neutral Cognition Therapeutics Positive Do analysts rate MDCX or CGTX? Medicus Pharma presently has a consensus target price of $23.50, suggesting a potential upside of 1,075.00%. Cognition Therapeutics has a consensus target price of $2.83, suggesting a potential upside of 64.25%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Medicus Pharma is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Cognition Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders and institutionals hold more shares of MDCX or CGTX? 43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MDCX or CGTX more profitable? Cognition Therapeutics' return on equity of -251.23% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -549.30% -228.06% Cognition Therapeutics N/A -251.23%-130.75% SummaryCognition Therapeutics beats Medicus Pharma on 8 of the 13 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.14M$3.12B$5.67B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.4920.6830.4025.56Price / SalesN/A362.39463.46115.41Price / CashN/A43.0338.2159.48Price / Book8.338.618.996.13Net Income-$11.16M-$54.65M$3.25B$264.98M7 Day Performance1.52%6.00%4.59%2.67%1 Month Performance-32.66%8.91%6.61%3.10%1 Year PerformanceN/A13.77%30.19%24.93% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.1528 of 5 stars$2.00+1.0%$23.50+1,075.0%N/A$27.14MN/A-1.49N/AEarnings ReportAnalyst ForecastCGTXCognition Therapeutics3.4738 of 5 stars$1.45+18.4%$2.83+96.1%+169.6%$107.42MN/A-2.1820News CoverageShort Interest ↓Analyst RevisionZNTLZentalis Pharmaceuticals2.0498 of 5 stars$1.49-0.3%$8.20+452.2%-48.9%$107.12M$26.87M-0.66160HLVXHilleVax1.5998 of 5 stars$2.08+0.2%$2.00-3.6%+23.8%$104.04MN/A-1.4520COYACoya Therapeutics1.8317 of 5 stars$6.20+0.1%$16.50+166.0%+18.0%$103.79M$3.55M-5.006News CoverageEarnings ReportAnalyst ForecastOKYOOKYO Pharma3.1034 of 5 stars$2.75+2.8%$7.00+155.0%+164.0%$103.24MN/A0.007Gap UpCRDLCardiol Therapeutics2.5408 of 5 stars$1.22+9.9%$8.00+555.7%-32.7%$102.52MN/A-3.6520News CoverageEarnings ReportHigh Trading VolumeANEBAnebulo Pharmaceuticals2.2488 of 5 stars$2.48+3.1%$5.50+122.2%+26.8%$101.69MN/A-9.524Short Interest ↑Gap UpTCRXTScan Therapeutics3.6779 of 5 stars$1.80+1.4%$7.80+334.5%-67.9%$101.58M$6.96M-1.65100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionATOSAtossa Genetics2.7307 of 5 stars$0.79-0.1%$6.17+685.6%-37.1%$101.53MN/A-3.428Earnings ReportAnalyst RevisionMGNXMacroGenics4.3392 of 5 stars$1.56-6.0%$5.40+245.9%-51.5%$98.74M$149.96M-1.76430Trending NewsEarnings ReportUpcoming EarningsGap Down Related Companies and Tools Related Companies Cognition Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives HilleVax Alternatives Coya Therapeutics Alternatives OKYO Pharma Alternatives Cardiol Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives TScan Therapeutics Alternatives Atossa Genetics Alternatives MacroGenics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access